Ask AI
ProCE Banner Activity

My Thoughts on the Clinical Implications of the Expanded Indication for Niraparib

Clinical Thought
Gain expert insights from Kathleen Moore, MD, on key findings from the QUADRA trial that led to FDA label expansion of niraparib in ovarian cancer.

Released: November 26, 2019

Share

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by independent educational grants from

Clovis Oncology

Tesaro

Faculty Disclosure

Primary Author

Kathleen N. Moore, MD, MS, FASCO

Deputy Director
Co-Director Cancer Therapeutics Program
Stephenson Cancer Center at OU Health
Professor, Gynecologic Oncology
University of Oklahoma, HSC
Oklahoma City, Oklahoma

Kathleen Moore, MD, has disclosed that she has received consulting fees from Aravive, AstraZeneca, Clovis, Cue Biopharma, Genentech/Roche, Merck, OncoMed, Pfizer, Samumed, Tesaro, and VBL Therapeutics.